RxDoctor Payments Data

John Koontz, MD

Family Medicine · Oklahoma City, OKNPI 1881666071

Payments from drug & device makers

$7,227in general payments, 2019–2025

Across 432 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Pfizer$721
  • AbbVie$679
  • Lilly USA, LLC$576
  • Astellas Pharma US Inc$363
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$7,12799%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,227 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$145,804
Medicare patients
429
Services billed
4,428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide85$124,983
JardianceEmpagliflozin72$83,907
FarxigaDapagliflozin Propanediol44$49,729
Tresiba Flextouch U-200Insulin Degludec27$28,986
MounjaroTirzepatide17$28,523
EliquisApixaban30$26,778
TrulicityDulaglutide16$24,632
JanuviaSitagliptin Phosphate15$23,161
Tresiba Flextouch U-100Insulin Degludec22$21,975
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$17,233
Breo ElliptaFluticasone/Vilanterol25$16,272
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$8,559
Omeprazole267$5,944
Atorvastatin Calcium489$5,147
SymbicortBudesonide/Formoterol Fumarate18$4,009

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,091$124,98385 claims
Boehringer IngelheimJardiance$279$83,90772 claims
AstraZenecaFarxiga, Symbicort$1,085$53,73862 claims
Lilly USA, LLCMounjaro, Trulicity$576$53,15533 claims
GSKTrelegy Ellipta, Breo Ellipta$278$33,50452 claims
PfizerEliquis$721$26,77830 claims
MerckJanuvia$178$23,16115 claims
AbbVieSynthroid$679$1,27126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →